Antiviral drug discovery against SARS-CoV.
Identifieur interne : 002287 ( PubMed/Checkpoint ); précédent : 002286; suivant : 002288Antiviral drug discovery against SARS-CoV.
Auteurs : Yu-Shan Wu [Taïwan] ; Wen-Hsing Lin ; John T-A Hsu ; Hsing-Pang HsiehSource :
- Current medicinal chemistry [ 0929-8673 ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Cysteine endopeptidases, Humains, Inhibiteurs de protéases (pharmacologie), Méthode des plages virales, Peptides (analyse), Protéines virales (antagonistes et inhibiteurs), RNA replicase (antagonistes et inhibiteurs), Tests de sensibilité microbienne (), Virus du SRAS ().
- MESH :
- analyse : Peptides.
- antagonistes et inhibiteurs : Protéines virales, RNA replicase.
- pharmacologie : Antiviraux, Inhibiteurs de protéases.
- Animaux, Cysteine endopeptidases, Humains, Méthode des plages virales, Tests de sensibilité microbienne, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Cysteine Endopeptidases, Humans, Microbial Sensitivity Tests (methods), Peptides (analysis), Protease Inhibitors (pharmacology), RNA Replicase (antagonists & inhibitors), SARS Virus (drug effects), Viral Plaque Assay, Viral Proteins (antagonists & inhibitors).
- MESH :
- chemical , analysis : Peptides.
- chemical , antagonists & inhibitors : RNA Replicase, Viral Proteins.
- chemical , pharmacology : Antiviral Agents, Protease Inhibitors.
- drug effects : SARS Virus.
- methods : Microbial Sensitivity Tests.
- Animals, Cysteine Endopeptidases, Humans, Viral Plaque Assay.
Abstract
Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M(pro); 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.
DOI: 10.2174/092986706777584988
PubMed: 16842194
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16842194Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral drug discovery against SARS-CoV.</title><author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name><affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350</wicri:regionArea><wicri:noRegion>Zhunan Town. Miaoli County 350</wicri:noRegion></affiliation></author><author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name></author><author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T-A" last="Hsu">John T-A Hsu</name></author><author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16842194</idno><idno type="pmid">16842194</idno><idno type="doi">10.2174/092986706777584988</idno><idno type="wicri:Area/PubMed/Corpus">002167</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002167</idno><idno type="wicri:Area/PubMed/Curation">002167</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002167</idno><idno type="wicri:Area/PubMed/Checkpoint">002287</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002287</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral drug discovery against SARS-CoV.</title><author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name><affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350</wicri:regionArea><wicri:noRegion>Zhunan Town. Miaoli County 350</wicri:noRegion></affiliation></author><author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name></author><author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T-A" last="Hsu">John T-A Hsu</name></author><author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name></author></analytic><series><title level="j">Current medicinal chemistry</title><idno type="ISSN">0929-8673</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Cysteine Endopeptidases</term><term>Humans</term><term>Microbial Sensitivity Tests (methods)</term><term>Peptides (analysis)</term><term>Protease Inhibitors (pharmacology)</term><term>RNA Replicase (antagonists & inhibitors)</term><term>SARS Virus (drug effects)</term><term>Viral Plaque Assay</term><term>Viral Proteins (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Cysteine endopeptidases</term><term>Humains</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Méthode des plages virales</term><term>Peptides (analyse)</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>RNA replicase (antagonistes et inhibiteurs)</term><term>Tests de sensibilité microbienne ()</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Peptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA Replicase</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term><term>RNA replicase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Microbial Sensitivity Tests</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cysteine Endopeptidases</term><term>Humans</term><term>Viral Plaque Assay</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cysteine endopeptidases</term><term>Humains</term><term>Méthode des plages virales</term><term>Tests de sensibilité microbienne</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M(pro); 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16842194</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0929-8673</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>17</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Current medicinal chemistry</Title><ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation></Journal><ArticleTitle>Antiviral drug discovery against SARS-CoV.</ArticleTitle><Pagination><MedlinePgn>2003-20</MedlinePgn></Pagination><Abstract><AbstractText>Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M(pro); 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Shan</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wen-Hsing</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>John T-A</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Hsing-Pang</ForeName><Initials>HP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Med Chem</MedlineTA><NlmUniqueID>9440157</NlmUniqueID><ISSNLinking>0929-8673</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA Replicase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16842194</ArticleId><ArticleId IdType="doi">10.2174/092986706777584988</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Taïwan</li></country></list><tree><noCountry><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T-A" last="Hsu">John T-A Hsu</name><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name></noCountry><country name="Taïwan"><noRegion><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002287 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002287 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16842194
|texte= Antiviral drug discovery against SARS-CoV.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16842194" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |